Inovio Pharmaceuticals, Inc., a late-stage biotechnology company, focuses on the discovery, development, and commercialization of DNA-based immunotherapies and vaccines to prevent and treat cancers and infectious diseases. Its SynCon immunotherapy design has the ability to break the immune system's tolerance of cancerous cells, as well as is intended to facilitate cross-strain protection against known, as well as new unmatched strains of pathogens, such as influenza. The company is involved in conducting and planning clinical studies of its proprietary SynCon immunotherapies for human papillomavirus-caused pre-cancers and cancers; bladder cancer; glioblastoma multiforme; hepatitis B virus; hepatitis C virus; human immunodeficiency virus; Ebola virus; middle east respiratory syndrome; and Zika virus. Its partners and collaborators include MedImmune, Limited; The Wistar Institute; University of Pennsylvania; GeneOne Life Science Inc.; ApolloBio Corporation; Regeneron Pharmaceuticals, Inc.; Genentech, Inc.; Plumbline Life Sciences, Inc.; Drexel University; National Institute of Allergy and Infectious Diseases; United States Military HIV Research Program; U.S. Army Medical Research Institute of Infectious Diseases; National Institutes of Health; HIV Vaccines Trial Network; Defense Advanced Research Projects Agency; the Parker Institute for Cancer Immunotherapy; and Coalition for Epidemic Preparedness Innovations. Inovio Pharmaceuticals, Inc. was founded in 1979 and is headquartered in Plymouth Meeting, Pennsylvania.
Industry, Sector and Symbol
Industry Surgical & medical instruments
Sub-IndustryN/A
SectorMedical
Phone267-440-4200
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$30.48 million
Profitability
Miscellaneous
Employees281
Next Earnings Date5/8/2019 (Estimated)
OptionableOptionable
Inovio Pharmaceuticals (NASDAQ:INO) Frequently Asked Questions
What is Inovio Pharmaceuticals' stock symbol?
Inovio Pharmaceuticals trades on the NASDAQ under the ticker symbol "INO."
When did Inovio Pharmaceuticals' stock split? How did Inovio Pharmaceuticals' stock split work?
Inovio Pharmaceuticals's stock reverse split on Friday, June 6th 2014. The 1-4 reverse split was announced on Friday, May 23rd 2014. The number of shares owned by shareholders was adjusted after the market closes on Thursday, June 5th 2014. An investor that had 100 shares of Inovio Pharmaceuticals stock prior to the reverse split would have 25 shares after the split.
How were Inovio Pharmaceuticals' earnings last quarter?
Inovio Pharmaceuticals Inc (NASDAQ:INO) issued its quarterly earnings results on Tuesday, March, 12th. The biopharmaceutical company reported ($0.34) earnings per share for the quarter, missing the Zacks' consensus estimate of ($0.31) by $0.03. The biopharmaceutical company had revenue of $2.50 million for the quarter, compared to analyst estimates of $2.69 million. Inovio Pharmaceuticals had a negative net margin of 318.11% and a negative return on equity of 93.39%. During the same quarter in the previous year, the company posted ($0.23) EPS. View Inovio Pharmaceuticals' Earnings History.
When is Inovio Pharmaceuticals' next earnings date?
What price target have analysts set for INO?
4 brokers have issued twelve-month price targets for Inovio Pharmaceuticals' shares. Their predictions range from $3.62 to $13.00. On average, they anticipate Inovio Pharmaceuticals' stock price to reach $8.1550 in the next year. This suggests a possible upside of 112.4% from the stock's current price. View Analyst Price Targets for Inovio Pharmaceuticals.
What is the consensus analysts' recommendation for Inovio Pharmaceuticals?
4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Inovio Pharmaceuticals in the last year. There are currently 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Inovio Pharmaceuticals.
What are Wall Street analysts saying about Inovio Pharmaceuticals stock?
Here are some recent quotes from research analysts about Inovio Pharmaceuticals stock:
- 1. Maxim Group analysts commented, "Inovio and its collaborators from The Wistar Institute presented positive preclinical data from its novel dBiTE (DNA-Encoded Bi-specific T Cell Engager) program at the American Association for Cancer Research (AACR) annual meeting." (4/3/2019)
- 2. HC Wainwright analysts commented, "916-3963, Probability of success (POS) Prob-adj Value Full value S/O as of POLT, U.S. 10% $0.03 $0.34 Shares outstanding 33,165 Emricasan for cirrhosis, U.S." (3/22/2019)
- 3. According to Zacks Investment Research, "Inovio incurred wider-than-expected loss in Q4. Moreover, revenues missed estimates. The company’s progress with its lead pipeline candidate, VGX-3100, for the treatment of cervical dysplasia is encouraging. Apart from VGX-3100, Inovio also has some promising vaccine candidates in its portfolio, which are progressing well. Additionally, Inovio has collaboration with big pharma companies like Roche, Regeneron and AstraZeneca, which helps the company with their expertise for further growth. Moreover, the company’s targeted cervical cancer market holds untapped potential. However, the company has no approved product in its portfolio and its excessive dependence on its partners for funding the development of its pipeline candidates raises a concern. Shares of the company have underperformed the industry so far this year." (3/15/2019)
Has Inovio Pharmaceuticals been receiving favorable news coverage?
News articles about INO stock have trended somewhat positive this week, InfoTrie Sentiment Analysis reports. InfoTrie identifies positive and negative news coverage by reviewing more than six thousand news and blog sources. The firm ranks coverage of public companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Inovio Pharmaceuticals earned a news sentiment score of 1.5 on InfoTrie's scale. They also gave press coverage about the biopharmaceutical company a news buzz of 1.0 out of 10, meaning that recent news coverage is extremely unlikely to have an effect on the stock's share price in the near future.
Are investors shorting Inovio Pharmaceuticals?
Inovio Pharmaceuticals saw a increase in short interest during the month of March. As of March 15th, there was short interest totalling 12,095,842 shares, an increase of 28.8% from the February 28th total of 9,393,180 shares. Based on an average trading volume of 1,718,791 shares, the days-to-cover ratio is presently 7.0 days. Approximately 13.6% of the shares of the company are short sold. View Inovio Pharmaceuticals' Current Options Chain.
Who are some of Inovio Pharmaceuticals' key competitors?
Some companies that are related to Inovio Pharmaceuticals include Cardiovascular Systems (CSII), K2M Group (KTWO), AtriCure (ATRC), Silk Road Medical (SILK), Cryolife (CRY), Orthofix Medical (OFIX), Luminex (LMNX), Shockwave Medical (SWAV), Intersect ENT (XENT), Tactile Systems Technology (TCMD), Cerus (CERS), AngioDynamics (ANGO), OraSure Technologies (OSUR), SurModics (SRDX) and Axonics Modulation Technologies (AXNX).
What other stocks do shareholders of Inovio Pharmaceuticals own?
Who are Inovio Pharmaceuticals' key executives?
Inovio Pharmaceuticals' management team includes the folowing people:
- Dr. J. Joseph Kim, CEO, Pres & Director (Age 50)
- Mr. Peter D. Kies, Chief Financial Officer (Age 56)
- Dr. Jacqueline E. Shea, COO & Exec. VP (Age 53)
- Dr. Mark L. Bagarazzi, Chief Medical Officer (Age 58)
- Dr. Laurent M. Humeau, Chief Scientific Officer & Exec. VP (Age 52)
Who are Inovio Pharmaceuticals' major shareholders?
Inovio Pharmaceuticals' stock is owned by a number of of retail and institutional investors. Top institutional shareholders include Defender Capital LLC. (0.71%). Company insiders that own Inovio Pharmaceuticals stock include David B Weiner, Jong Joseph Kim, Peter Kies and Simon X Benito. View Institutional Ownership Trends for Inovio Pharmaceuticals.
Which institutional investors are buying Inovio Pharmaceuticals stock?
How do I buy shares of Inovio Pharmaceuticals?
Shares of INO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Inovio Pharmaceuticals' stock price today?
One share of INO stock can currently be purchased for approximately $3.84.
How big of a company is Inovio Pharmaceuticals?
Inovio Pharmaceuticals has a market capitalization of $374.89 million and generates $30.48 million in revenue each year. The biopharmaceutical company earns $-96,970,000.00 in net income (profit) each year or ($1.05) on an earnings per share basis. Inovio Pharmaceuticals employs 281 workers across the globe.
What is Inovio Pharmaceuticals' official website?
How can I contact Inovio Pharmaceuticals?
Inovio Pharmaceuticals' mailing address is 660 WEST GERMANTOWN PIKE SUITE 110, PLYMOUTH MEETING PA, 19462. The biopharmaceutical company can be reached via phone at 267-440-4200 or via email at [email protected]
MarketBeat Community Rating for Inovio Pharmaceuticals (NASDAQ INO)
MarketBeat's community ratings are surveys of what our community members think about Inovio Pharmaceuticals and other stocks. Vote "Outperform" if you believe INO will outperform the S&P 500 over the long term. Vote "Underperform" if you believe INO will underperform the S&P 500 over the long term. You may vote once every thirty days.
